Progressive Multifocal Leukoencephalopathy (PML), caused by the reactivation of JC virus (JCV), remains a life-threatening AIDS-defining infection of the central nervous system. In addition, PML also occurs in HIV- negative patients treated with monoclonal antibodies for cancer or autoimmune diseases. Although the shedding of JCV in the urine of healthy individual is asymptomatic, the reactivation of JCV in the brain of PML patients causes severe damages from destruction of myelin. Therefore, halting JC viral replication in the brain can prevent progression to PML. However, knowledge of the virologic and immunologic events occurring in the CNS prior to onset of PML is limited; better understanding of PML pathogenesis is hampered by the lack of an animal model. Our overall goal is to generate a mouse model of PML. Our central hypothesis is that a novel chimeric murine-JC polyomavirus, harboring the murine replication machinery and the neuropathogenic type JCV capsid will cause productive and lytic infection of mouse oligodendrocytes, and recapitulate the pathogenesis of PML in mice. The rationale is based on previous studies of murine polyomavirus and JCV strains isolated from the CSF of PML patients, indicating altered pathogenicity due to changes in the VP1 capsid, as well as our preliminary data demonstrating the creation of a novel chimeric murine-JC polyomavirus, rMPyV-JCVMad. A mouse model of PML is urgently needed to further our understanding of immune events leading to JCV reactivation and the development of PML. Such small animal model will be crucial in devising preventive and therapeutic strategies for PML in HIV+ and other immunosuppressed patients. Based on our strong preliminary data, we will test this hypothesis by pursuing these specific aims:
Aim 1. Characterize rMPyV-JCVMad chimeric virus in vitro.
Aim 2. Develop a mouse model of PML. The proposed studies draw upon our extensive experiences in molecular virology, histology, and prior mouse studies. The development of new tools, including the novel chimeric murine-JC polyomavirus will also be useful to other researchers and will pave the way for the discovery of new targets for prevention and treatment of PML. This proposed work will produce the first animal model of PML, which will expand our understanding of JCV pathogenesis in the CNS, and reveal new targets for therapeutic interventions.

Public Health Relevance

The proposed research is relevant to public health because it will have an important positive impact on development of an animal model of Progressive Multifocal Leukoencephalopathy (PML), a devastating and often fatal disease in HIV-infected and other immunocompromised individuals caused by the reactivation of JC virus (JCV). The proposed work will expand understanding of JCV biology and help develop new therapy for PML. The outcome of these studies will not only decrease mortality and morbidity in PML patients, but also benefit other patients with CNS viral infections. Thus, the proposed research is relevant to the part of NINDS's mission that pertains to developing fundamental knowledge to alleviate the burdens of neurological diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS090951-02
Application #
9036470
Study Section
NeuroAIDS and other End-Organ Diseases Study Section (NAED)
Program Officer
Wong, May
Project Start
2015-04-01
Project End
2017-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code